Exciting news! Lilly's #KisunlaTM (donanemab-azbt) has been approved by the #FDA for the treatment of early symptomatic #Alzheimer's disease. In its pivotal Phase 3 study, Kisunla demonstrated significant benefits, including slowing cognitive and functional decline by up to 35% compared to placebo at 18 months. It also reduced the risk of progressing to the next clinical stage of the disease by up to 39%. Kisunla is the first and only amyloid plaque-targeting therapy that offers a limited-duration treatment regimen based on amyloid plaque removal, potentially resulting in lower costs and fewer infusions. This approval brings hope to those affected by Alzheimer's disease and offers the potential to improve their quality of life! #hope #Alzheimersresearch #newtreatment
Breaking News: The FDA approved a new amyloid-targeting therapy to treat adults with early symptomatic #AlzheimersDisease. Learn more: https://e.lilly/4bsaOPk
Healthcare Advisor | Executive Leader Driving Strategic Partnerships & Innovative Planning
1dSuch excellent news